Other Vaccines - Senegal

Senegal

Highlights

In Senegal, the revenue in the market Other Vaccines market is forecasted to reach US$4.16m in 2024.
The revenue is anticipated to exhibit an annual growth rate (CAGR 2024-2029) of 11.18%, leading to a market volume of US$7.06m by 2029.
In terms of global comparison, United States is expected to generate the highest revenue, with US$24.73bn in 2024.
"Senegal has made significant strides in the development and distribution of other vaccines, contributing to improved healthcare outcomes in the country."

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

The Other Vaccines market in Senegal has been experiencing significant growth over the past few years.

Customer preferences: Senegal has a high demand for vaccines due to the high prevalence of infectious diseases in the country. The government has been actively promoting vaccination campaigns to reduce the incidence of diseases such as yellow fever, meningitis, and polio. Additionally, the population has become more aware of the importance of vaccination and is increasingly seeking out vaccines as a preventive measure.

Trends in the market: The market for Other Vaccines in Senegal has been growing steadily due to the increasing demand for vaccines. The government has been investing in the healthcare sector, which has resulted in better healthcare infrastructure and increased access to healthcare services. This has led to an increase in the number of healthcare facilities offering vaccines. Moreover, the government has been collaborating with international organizations to secure a steady supply of vaccines for the population.

Local special circumstances: Senegal is a low-income country, and the cost of vaccines can be a barrier for some individuals. To address this issue, the government has been providing vaccines for free or at a reduced cost to vulnerable populations. Additionally, the government has been partnering with international organizations to secure funding for vaccination campaigns.

Underlying macroeconomic factors: The Senegalese economy has been growing steadily over the past few years, which has resulted in increased government spending on healthcare. The government has been investing in the healthcare sector to improve the quality of healthcare services and increase access to healthcare for the population. This has led to an increase in the number of healthcare facilities offering vaccines and an increase in the number of individuals seeking out vaccines. Furthermore, the government has been collaborating with international organizations to secure a steady supply of vaccines for the population.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.